BAX
Baxter International Inc.NYSEHealthcare$16.68-0.60%OpenMarket Cap: $8.58B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.40
P/S
0.76
EV/EBITDA
21.40
DCF Value
$-1.40
FCF Yield
3.8%
Div Yield
2.2%
Margins & Returns
Gross Margin
30.1%
Operating Margin
-2.7%
Net Margin
-8.5%
ROE
-13.8%
ROA
-8.9%
ROIC
-1.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $2.97B | 19.4% | $-729.0M | $-1.13B | $-2.16 | $0.01 |
| FY 2025 | $11.24B | 30.1% | $-308.0M | $-957.0M | $-1.75 | $0.52 |
| Q3 2025 | $2.83B | 33.5% | $172.0M | $-46.0M | $-0.09 | $0.17 |
| Q2 2025 | $2.81B | 35.3% | $191.0M | $91.0M | $0.18 | $0.17 |
| Q1 2025 | $2.63B | 32.8% | $58.0M | $126.0M | $0.25 | $0.17 |
| Q4 2024 | $2.75B | 34.8% | $-435.0M | $-512.0M | $-1.00 | $0.17 |
| FY 2024 | $10.64B | 37.5% | $14.0M | $-649.0M | $-1.27 | $1.04 |
| Q3 2024 | $2.70B | 38.3% | $155.0M | $140.0M | $0.27 | $0.29 |
| Q2 2024 | $2.69B | 38.3% | $179.0M | $-314.0M | $-0.61 | $0.29 |
| Q1 2024 | $2.49B | 38.6% | $115.0M | $37.0M | $0.07 | $0.29 |
| Q4 2023 | $3.88B | 37.9% | $329.0M | $245.0M | $0.48 | $0.29 |
| FY 2023 | $10.36B | 40.1% | $707.0M | $2.66B | $5.23 | $1.16 |